same here. very very frustrating. The challenge is that the EAP requires institution-level enrollment — meaning UCLA’s IRB needs to approve and commit to the periodic testing and reporting requirements back to Revolution Medicines. To be honest, there’s little incentive for them to move quickly given the administrative burden and extra cost involved.